Skip to main content
Premium Trial:

Request an Annual Quote

AltheaDx, Compendia Partner on Breast Cancer Assay

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – AltheaDx today said that it has formed a partnership with Compendia Bioscience to combine their technologies to create tests that can predict patient outcomes in clinical trials.

The initial product developed under the collaboration is the Breast Cancer Segregation Panel Assay — a real-time, PCR-based panel that has been optimized for analysis of RNA extracted from formalin-fixed, paraffin-embedded tissue. The panel includes 96 genes associated with breast cancer identified through a meta-analysis of cancer genomic data from more than 5,000 clinical samples, said AltheaDx.

Under the collaboration, AltheaDx will process and analyze samples at its San Diego-based CLIA and GLP lab. Compendia will manage downstream data analysis and statistical correlation to patient outcomes in clinical trials.

The firms also said that they plan to develop Segregation Panels for other cancer types, with the launch of a Colorectal Cancer Segregation Panel expected to be launched in 2011.

Further terms of the alliance were not disclosed.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.